Dietary intake of specific amino acids and liver status in subjects with nonalcoholic fatty liver disease: fatty liver in obesity (FLiO) study

Galarregui, Cristina; Cantero, Irene; Marín-Alejandre, Bertha Araceli; Monreal, J Ignacio; Elorz, Mariana; Benito, Alberto; Herrero, J.I.; O, Víctor de la; Ruiz‐Canela, Miguel; Hermsdorff, Helen Hermana Miranda; Bressan, Josefina; Tur, Josep A.; Martínéz, J. Alfredo; Zulet, M. Ángeles; Abete, Itziar

doi:10.1007/s00394-020-02370-6

Cited by 20 publications

(11 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study highlighted the crucial association between impaired BCAA metabolism and the manifestation of NAFLD [ 56 ]. In obese NAFLD patients, a higher consumption of BCAAs was associated with worse hepatic health in terms of liver fat content [ 57 ].…”

Section: Circulatory Bcaas Level As An Indicator Of a Dysmetabolic Statementioning

confidence: 99%

The Emerging Role of Branched-Chain Amino Acids in Liver Diseases

Felicianna

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Chronic liver diseases pose a substantial health burden worldwide, with approximately two million deaths each year. Branched-chain amino acids (BCAAs)—valine, leucine, and isoleucine—are a group of essential amino acids that are essential for human health. Despite the necessity of a dietary intake of BCAA, emerging data indicate the undeniable correlation between elevated circulating BCAA levels and chronic liver diseases, including non-alcoholic fatty liver diseases (NAFLD), cirrhosis, and hepatocellular carcinoma (HCC). Moreover, circulatory BCAAs were positively associated with a higher cholesterol level, liver fat content, and insulin resistance (IR). However, BCAA supplementation was found to provide positive outcomes in cirrhosis and HCC patients. This review will attempt to address the contradictory claims found in the literature, with a special focus on BCAAs’ distribution, key signaling pathways, and the modulation of gut microbiota. This should provide a better understanding of BCAAs’ possible contribution to liver health.

show abstract

Section: Circulatory Bcaas Level As An Indicator Of a Dysmetabolic Statementioning

confidence: 99%

The Emerging Role of Branched-Chain Amino Acids in Liver Diseases

Felicianna

et al. 2022

Biomedicines

View full text Add to dashboard Cite

show abstract

“…BCAAs are also involved in the development of nonalcoholic fatty liver disease (NAFLD), a common complication of obesity. 82 Our previous studies also indicated a relationship between high serum BCAA levels and IR in patients with morbid obesity. 66 Moreover, we have shown that BCAA levels decline after BS, a finding that we associated with a potential increase in the synthesis of BCFAs from BCAAs in adipose tissue.…”

Section: Amino Acidsmentioning

confidence: 80%

The impact of the interplay of the intestinal microbiome and diet on the metabolomic and health outcomes of bariatric surgery

et al. 2022

View full text Add to dashboard Cite

Summary Obesity has evolved into a global epidemic. Bariatric surgery, the most effective treatment for obesity, keeps many comorbidities of obesity at bay for a prolonged period of time. However, complications, including metabolic alterations, are inherent in bariatric surgery. Surgical intervention in the structure of the digestive tract, especially during bariatric bypass procedures, also causes significant changes in the composition of the microbiome, which may affect the composition and quantity of various metabolites produced by intestinal bacteria. The composition of the intestinal microbiome is connected to human metabolism via metabolites that are produced and secreted by bacterial cells into the intestinal lumen and then absorbed into the host's bloodstream. Bariatric surgery causes changes in the composition and quantity of many circulating metabolites. Metabolic disorders may be affected after bariatric surgery by changes in the composition of the microbiome and metabolites produced by bacteria.

show abstract

“…However, the effect of the high protein diet in patients with NAFLD remains controversial. On the one hand, it has been suggested that the consumption of specific dietary amino acids might negatively impact liver status and, to a lesser extent, glucose metabolism in subjects with overweight/obesity and NAFLD [81]. Moreover, high protein intake derived mainly from dairy products has been associated with higher risk to develop diabetes and also with NAFLD [82].…”

Section: Discussionmentioning

confidence: 99%

Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global population. The pathogenesis of NAFLD is complex; available data reveal that genetics and ascribed interactions with environmental factors may play an important role in the development of this morbid condition. The purpose of this investigation was to assess genetic and non-genetic determinants putatively involved in the onset and progression of NAFLD after a 6-month weight loss nutritional treatment. A group of 86 overweight/obese subjects with NAFLD from the Fatty Liver in Obesity (FLiO) study were enrolled and metabolically evaluated at baseline and after 6 months. A pre-designed panel of 95 genetic variants related to obesity and weight loss was applied and analyzed. Three genetic risk scores (GRS) concerning the improvement on hepatic health evaluated by minimally invasive methods such as the fatty liver index (FLI) (GRSFLI), lipidomic-OWLiver®-test (GRSOWL) and magnetic resonance imaging (MRI) (GRSMRI), were derived by adding the risk alleles genotypes. Body composition, liver injury-related markers and dietary intake were also monitored. Overall, 23 SNPs were independently associated with the change in FLI, 16 SNPs with OWLiver®-test and 8 SNPs with MRI, which were specific for every diagnosis tool. After adjusting for gender, age and other related predictors (insulin resistance, inflammatory biomarkers and dietary intake at baseline) the calculated GRSFLI, GRSOWL and GRSMRI were major contributors of the improvement in hepatic status. Thus, fitted linear regression models showed a variance of 53% (adj. R2 = 0.53) in hepatic functionality (FLI), 16% (adj. R2 = 0.16) in lipidomic metabolism (OWLiver®-test) and 34% (adj. R2 = 0.34) in liver fat content (MRI). These results demonstrate that three different genetic scores can be useful for the personalized management of NAFLD, whose treatment must rely on specific dietary recommendations guided by the measurement of specific genetic biomarkers.

show abstract

Dietary intake of specific amino acids and liver status in subjects with nonalcoholic fatty liver disease: fatty liver in obesity (FLiO) study

Cited by 20 publications

References 59 publications

The Emerging Role of Branched-Chain Amino Acids in Liver Diseases

The Emerging Role of Branched-Chain Amino Acids in Liver Diseases

The impact of the interplay of the intestinal microbiome and diet on the metabolomic and health outcomes of bariatric surgery

Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study

Contact Info

Product

Resources

About